Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints ...

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026. In September ...

The company recently reported positive phase 3 results for Mim8 in patients with hemophilia. It has products across several other fields: Alzheimer's disease, Parkinson's disease, thalassemia ...

From the list of its product candidates, which you can also see below, I highlight ziltivekimab, Mim8, amycretin, coramitug, and etavopivat, which, in my opinion, will not only be able to return ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) recently ...

The data showed that Mim8 was well-tolerated and efficacious in children with haemophilia A with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment with ...